openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS: Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. If such a reaction occurs, therapy with Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) should be stopped at once and alternative treatment should be considered.
ADVERSE REACTIONS: Adverse reaction information on Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) in patients with perennial rhinitis was derived from four multicenter, vehicle-controlled clinical trials involving 703 patients (356 patients on ipratropium bromide and 347 patients on vehicle), and a one-year, open-label, follow-up trial. In three of the trials, patients received Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) three times daily, for eight weeks. In the other trial, Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) was given to patients two times daily for four weeks. Of the 285 patients who entered the open-label, follow-up trial, 232 were treated for 3 months, 200 for 6 months, and 159 up to one year. The majority (>86%) of patients treated for one year were maintained on 42 mcg per nostril, two or three times daily, of Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray). Table 1 shows adverse events, and the frequency that these adverse events led to the discontinuation of treatment, reported for patients who received Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) at the recommended dose of 42 mcg per nostril, or vehicle two or three times daily for four or eight weeks. Only adverse events reported with an incidence of at least 2.0% in the ipratropium bromide group and higher in the ipratropium bromide group than in the vehicle group are shown. Table 1: % of Patients Reporting Events This table includes adverse events which occurred at an incidence rate of at least 2.0% in the ipratropium bromide group and more frequently in the ipratropium bromide group than in the vehicle group. Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) (n=356) Incidence% Discontinued% Headache 9.8 0.6 Upper respiratory tract infection 9.8 1.4 Epistaxis Epistaxis reported by 7.0% of ipratropium bromide patients and 2.3% of vehicle patients, blood-tinged mucus by 2.0% of ipratropium bromide patients and 2.3% of vehicle patients. 9.0 0.3 Rhinitis All events are listed by their WHO term; rhinitis has been presented by descriptive terms for clarification. Nasal dryness 5.1 0.0 Nasal irritation Nasal irritation includes reports of nasal itching, nasal burning, nasal irritation, and ulcerative rhinitis. 2.0 0.0 Other nasal symptoms Other nasal symptoms include reports of nasal congestion, increased rhinorrhea, increased rhinitis, posterior nasal drip, sneezing, nasal polyps, and nasal edema. 3.1 1.1 Pharyngitis 8.1 0.3 Nausea 2.2 0.3 Vehicle Control (n=347) Incidence% Discontinued% Headache 9.2 0.0 Upper respiratory tract infection 7.2 1.4 Epistaxis 4.6 0.3 Rhinitis Nasal dryness 0.9 0.3 Nasal irritation 1.7 0.6 Other nasal symptoms 1.7 0.3 Pharyngitis 4.6 0.0 Nausea 0.9 0.0 Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) was well tolerated by most patients. The most frequently reported nasal adverse events were transient episodes of nasal dryness or epistaxis. These adverse events were mild or moderate in nature, none was considered serious, none resulted in hospitalization and most resolved spontaneously or following a dose reduction. Treatment for nasal dryness and epistaxis was required infrequently (2% or less) and consisted of local application of pressure or a moisturizing agent (e.g., petroleum jelly or saline nasal spray). Patient discontinuation for epistaxis or nasal dryness was infrequent in both the controlled (0.3% or less) and one-year, open-label (2% or less) trials. There was no evidence of nasal rebound (i.e., a clinically significant increase in rhinorrhea, posterior nasal drip, sneezing or nasal congestion severity compared to baseline) upon discontinuation of double-blind therapy in these trials. Adverse events reported by less than 2% of the patients receiving Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) during the controlled clinical trials or during the open-label follow-up trial, which are potentially related to ipratropium bromide’s local effects or systemic anticholinergic effects include: dry mouth/throat, dizziness, ocular irritation, blurred vision, conjunctivitis, hoarseness, cough, and taste perversion. There were infrequent reports of skin rash in both the controlled and uncontrolled clinical studies. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table ID="_RefID0EXMAC" width="100%"><caption>Table 1: % of Patients Reporting Events<footnote ID="_Ref74146999">This table includes adverse events which occurred at an incidence rate of at least 2.0% in the ipratropium bromide group and more frequently in the ipratropium bromide group than in the vehicle group.</footnote></caption><col width="33%"/><col width="33%"/><col width="33%"/><tbody><tr><td align="center" colspan="3" styleCode="Rrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Ipratropium Bromide Nasal </content></paragraph></td></tr><tr><td align="center" colspan="3" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Solution 0.03% (Nasal Spray)</content></paragraph></td></tr><tr><td align="center" colspan="3" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">(n=356)</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"/><td valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Lrule " valign="top"/><td align="center" valign="top"><paragraph><content styleCode="bold">Incidence%</content></paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph><content styleCode="bold">Discontinued%</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" valign="top"><paragraph>9.8</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Upper respiratory tract infection</paragraph></td><td align="center" valign="top"><paragraph>9.8</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1.4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Epistaxis<footnote ID="_Ref74147089">Epistaxis reported by 7.0% of ipratropium bromide patients and 2.3% of vehicle patients, blood-tinged mucus by 2.0% of ipratropium bromide patients and 2.3% of vehicle patients.</footnote></paragraph></td><td align="center" valign="top"><paragraph>9.0</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.3</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Rhinitis<footnote ID="_Ref74147135">All events are listed by their WHO term; rhinitis has been presented by descriptive terms for clarification.</footnote></paragraph></td><td valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Lrule " valign="top"><paragraph> Nasal dryness</paragraph></td><td align="center" valign="top"><paragraph>5.1</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph> Nasal irritation<footnote ID="_Ref74147161">Nasal irritation includes reports of nasal itching, nasal burning, nasal irritation, and ulcerative rhinitis.</footnote></paragraph></td><td align="center" valign="top"><paragraph>2.0</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph> Other nasal symptoms<footnote ID="_Ref74147179">Other nasal symptoms include reports of nasal congestion, increased rhinorrhea, increased rhinitis, posterior nasal drip, sneezing, nasal polyps, and nasal edema.</footnote></paragraph></td><td align="center" valign="top"><paragraph>3.1</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1.1</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Pharyngitis</paragraph></td><td align="center" valign="top"><paragraph>8.1</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.3</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Nausea</paragraph></td><td align="center" valign="top"><paragraph>2.2</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.3</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"/><td valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td align="center" colspan="3" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Vehicle Control</content></paragraph></td></tr><tr><td align="center" colspan="3" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">(n=347)</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"/><td align="center" valign="top"><paragraph><content styleCode="bold">Incidence%</content></paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph><content styleCode="bold">Discontinued%</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" valign="top"><paragraph>9.2</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Upper respiratory tract infection</paragraph></td><td align="center" valign="top"><paragraph>7.2</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1.4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Epistaxis<footnoteRef IDREF="_Ref74147089"/></paragraph></td><td align="center" valign="top"><paragraph>4.6</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.3</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Rhinitis<footnoteRef IDREF="_Ref74147135"/></paragraph></td><td valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Lrule " valign="top"><paragraph> Nasal dryness</paragraph></td><td align="center" valign="top"><paragraph>0.9</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.3</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph> Nasal irritation<footnoteRef IDREF="_Ref74147161"/></paragraph></td><td align="center" valign="top"><paragraph>1.7</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph> Other nasal symptoms<footnoteRef IDREF="_Ref74147179"/></paragraph></td><td align="center" valign="top"><paragraph>1.7</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.3</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Pharyngitis</paragraph></td><td align="center" valign="top"><paragraph>4.6</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Nausea</paragraph></td><td align="center" valign="top"><paragraph>0.9</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>0.0</paragraph></td></tr><tr><td styleCode="Botrule Lrule " valign="top"/><td styleCode="Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"/></tr></tbody></table>